Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper

I Baiardini, F Braido, Carsten Bindslev-Jensen, P J Bousquet, Z Brzoza, G W Canonica, E Compalati, A Fiocchi, W Fokkens, R Gerth van Wijk, A Giménez-Arnau, K Godse, C Grattan, J J Grob, S La Grutta, D Kalogeromitros, E Kocatürk, C Lombardi, A Mota-Pinto, E Ridolo & 9 andre S S Saini, M Sanchez-Borges, G E Senna, I Terreehorst, A Todo Bom, E Toubi, J Bousquet, T Zuberbier, Marcus Maurer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations and suggestions for assessing patient-reported outcomes (PROs) including health-related quality of life in patients with urticaria. We recommend that PROs should be used both in clinical trials and routine practice for the evaluation of urticaria patients. We suggest that PROs should be considered as the primary outcome of future clinical trials. Two validated and disease-specific instruments for assessing PROs are available, the urticaria activity score (for symptoms) and the chronic urticaria questionnaire on quality of life CU-Q(2)oL. This latter tool, CU-Q(2)oL, is available in many languages and should be preferred, where available, over more generic instruments for assessing urticaria-specific effects on quality of life. CU-Q(2)oL is only suited for the investigation of patients with chronic spontaneous urticaria. Similar instruments for other forms of urticaria have yet to be developed and validated. Also, tools for assessing other chronic spontaneous urticaria PROs besides quality of life and symptoms are needed.
OriginalsprogEngelsk
BogserieAllergy: European Journal of Allergy and Clinical Immunology, Supplement
Vol/bind66
Udgave nummer7
Sider (fra-til)840-4
Antal sider5
ISSN0108-1675
DOI
StatusUdgivet - 2011

Fingeraftryk

Urticaria
Quality of Life
Clinical Trials
Consensus
Hypersensitivity
Language

Citer dette

Baiardini, I ; Braido, F ; Bindslev-Jensen, Carsten ; Bousquet, P J ; Brzoza, Z ; Canonica, G W ; Compalati, E ; Fiocchi, A ; Fokkens, W ; Gerth van Wijk, R ; Giménez-Arnau, A ; Godse, K ; Grattan, C ; Grob, J J ; La Grutta, S ; Kalogeromitros, D ; Kocatürk, E ; Lombardi, C ; Mota-Pinto, A ; Ridolo, E ; Saini, S S ; Sanchez-Borges, M ; Senna, G E ; Terreehorst, I ; Todo Bom, A ; Toubi, E ; Bousquet, J ; Zuberbier, T ; Maurer, Marcus. / Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. I: Allergy: European Journal of Allergy and Clinical Immunology, Supplement. 2011 ; Bind 66, Nr. 7. s. 840-4.
@article{76c1a7768d7a414c8510e078516a53d8,
title = "Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper",
abstract = "The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations and suggestions for assessing patient-reported outcomes (PROs) including health-related quality of life in patients with urticaria. We recommend that PROs should be used both in clinical trials and routine practice for the evaluation of urticaria patients. We suggest that PROs should be considered as the primary outcome of future clinical trials. Two validated and disease-specific instruments for assessing PROs are available, the urticaria activity score (for symptoms) and the chronic urticaria questionnaire on quality of life CU-Q(2)oL. This latter tool, CU-Q(2)oL, is available in many languages and should be preferred, where available, over more generic instruments for assessing urticaria-specific effects on quality of life. CU-Q(2)oL is only suited for the investigation of patients with chronic spontaneous urticaria. Similar instruments for other forms of urticaria have yet to be developed and validated. Also, tools for assessing other chronic spontaneous urticaria PROs besides quality of life and symptoms are needed.",
keywords = "Chronic Disease, Clinical Trials as Topic, Humans, Outcome Assessment (Health Care), Quality of Life, Questionnaires, Treatment Outcome, Urticaria",
author = "I Baiardini and F Braido and Carsten Bindslev-Jensen and Bousquet, {P J} and Z Brzoza and Canonica, {G W} and E Compalati and A Fiocchi and W Fokkens and {Gerth van Wijk}, R and A Gim{\'e}nez-Arnau and K Godse and C Grattan and Grob, {J J} and {La Grutta}, S and D Kalogeromitros and E Kocat{\"u}rk and C Lombardi and A Mota-Pinto and E Ridolo and Saini, {S S} and M Sanchez-Borges and Senna, {G E} and I Terreehorst and {Todo Bom}, A and E Toubi and J Bousquet and T Zuberbier and Marcus Maurer",
note = "{\circledC} 2011 John Wiley & Sons A/S.",
year = "2011",
doi = "10.1111/j.1398-9995.2011.02580.x",
language = "English",
volume = "66",
pages = "840--4",
journal = "Allergy: European Journal of Allergy and Clinical Immunology, Supplement",
issn = "0108-1675",
publisher = "Wiley-Blackwell",
number = "7",

}

Baiardini, I, Braido, F, Bindslev-Jensen, C, Bousquet, PJ, Brzoza, Z, Canonica, GW, Compalati, E, Fiocchi, A, Fokkens, W, Gerth van Wijk, R, Giménez-Arnau, A, Godse, K, Grattan, C, Grob, JJ, La Grutta, S, Kalogeromitros, D, Kocatürk, E, Lombardi, C, Mota-Pinto, A, Ridolo, E, Saini, SS, Sanchez-Borges, M, Senna, GE, Terreehorst, I, Todo Bom, A, Toubi, E, Bousquet, J, Zuberbier, T & Maurer, M 2011, 'Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper', Allergy: European Journal of Allergy and Clinical Immunology, Supplement, bind 66, nr. 7, s. 840-4. https://doi.org/10.1111/j.1398-9995.2011.02580.x

Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. / Baiardini, I; Braido, F; Bindslev-Jensen, Carsten; Bousquet, P J; Brzoza, Z; Canonica, G W; Compalati, E; Fiocchi, A; Fokkens, W; Gerth van Wijk, R; Giménez-Arnau, A; Godse, K; Grattan, C; Grob, J J; La Grutta, S; Kalogeromitros, D; Kocatürk, E; Lombardi, C; Mota-Pinto, A; Ridolo, E; Saini, S S; Sanchez-Borges, M; Senna, G E; Terreehorst, I; Todo Bom, A; Toubi, E; Bousquet, J; Zuberbier, T; Maurer, Marcus.

I: Allergy: European Journal of Allergy and Clinical Immunology, Supplement, Bind 66, Nr. 7, 2011, s. 840-4.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper

AU - Baiardini, I

AU - Braido, F

AU - Bindslev-Jensen, Carsten

AU - Bousquet, P J

AU - Brzoza, Z

AU - Canonica, G W

AU - Compalati, E

AU - Fiocchi, A

AU - Fokkens, W

AU - Gerth van Wijk, R

AU - Giménez-Arnau, A

AU - Godse, K

AU - Grattan, C

AU - Grob, J J

AU - La Grutta, S

AU - Kalogeromitros, D

AU - Kocatürk, E

AU - Lombardi, C

AU - Mota-Pinto, A

AU - Ridolo, E

AU - Saini, S S

AU - Sanchez-Borges, M

AU - Senna, G E

AU - Terreehorst, I

AU - Todo Bom, A

AU - Toubi, E

AU - Bousquet, J

AU - Zuberbier, T

AU - Maurer, Marcus

N1 - © 2011 John Wiley & Sons A/S.

PY - 2011

Y1 - 2011

N2 - The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations and suggestions for assessing patient-reported outcomes (PROs) including health-related quality of life in patients with urticaria. We recommend that PROs should be used both in clinical trials and routine practice for the evaluation of urticaria patients. We suggest that PROs should be considered as the primary outcome of future clinical trials. Two validated and disease-specific instruments for assessing PROs are available, the urticaria activity score (for symptoms) and the chronic urticaria questionnaire on quality of life CU-Q(2)oL. This latter tool, CU-Q(2)oL, is available in many languages and should be preferred, where available, over more generic instruments for assessing urticaria-specific effects on quality of life. CU-Q(2)oL is only suited for the investigation of patients with chronic spontaneous urticaria. Similar instruments for other forms of urticaria have yet to be developed and validated. Also, tools for assessing other chronic spontaneous urticaria PROs besides quality of life and symptoms are needed.

AB - The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations and suggestions for assessing patient-reported outcomes (PROs) including health-related quality of life in patients with urticaria. We recommend that PROs should be used both in clinical trials and routine practice for the evaluation of urticaria patients. We suggest that PROs should be considered as the primary outcome of future clinical trials. Two validated and disease-specific instruments for assessing PROs are available, the urticaria activity score (for symptoms) and the chronic urticaria questionnaire on quality of life CU-Q(2)oL. This latter tool, CU-Q(2)oL, is available in many languages and should be preferred, where available, over more generic instruments for assessing urticaria-specific effects on quality of life. CU-Q(2)oL is only suited for the investigation of patients with chronic spontaneous urticaria. Similar instruments for other forms of urticaria have yet to be developed and validated. Also, tools for assessing other chronic spontaneous urticaria PROs besides quality of life and symptoms are needed.

KW - Chronic Disease

KW - Clinical Trials as Topic

KW - Humans

KW - Outcome Assessment (Health Care)

KW - Quality of Life

KW - Questionnaires

KW - Treatment Outcome

KW - Urticaria

U2 - 10.1111/j.1398-9995.2011.02580.x

DO - 10.1111/j.1398-9995.2011.02580.x

M3 - Journal article

VL - 66

SP - 840

EP - 844

JO - Allergy: European Journal of Allergy and Clinical Immunology, Supplement

JF - Allergy: European Journal of Allergy and Clinical Immunology, Supplement

SN - 0108-1675

IS - 7

ER -